Healthcare / Medical DevicesKOSDAQ
$6550.00
-250.00 (-3.68%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-424.8M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$35.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-9.9%
↓Gross Margin
48.3%
↓Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.4%
FCF CAGR
—
FCF margin
-36.6%
FCF / Net income
1.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.52B · net income $-1.88B · FCF $-3.49B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.52B | $9.52B | $9.96B | $10.15B | $8.14B |
| Net Income | $-1.88B | $-1.88B | $-24.2M | $1.18B | $239.6M |
| EBITDA | $-1.50B | $-1.50B | $906.4M | $2.34B | $1.51B |
| EPS | -346.00 | -346.00 | -5.00 | 257.00 | 53.00 |
| Gross Margin | 48.3% | 48.3% | 57.3% | 55.5% | 54.1% |
| Operating Margin | -27.1% | -27.1% | -0.3% | 8.6% | -8.1% |
| Net Margin | -19.7% | -19.7% | -0.2% | 11.6% | 2.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.19 | 0.34 | 0.48 |
| Current Ratio | 5.78 | 5.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.49B | $-3.49B | $-424.8M | $1.04B | $-2.13B |
| Returns | |||||
| ROE | -9.9% | -9.9% | -0.1% | 9.3% | 2.1% |
| Valuation | |||||
| EV/EBITDA | — | — | 58.13 | — | — |
| P/B | 1.87 | 1.87 | 2.85 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -4.4% | -4.4% | -1.9% | 24.7% | — |
| EPS Growth | -6820.0% | -6820.0% | -101.9% | 384.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.00 → -346.00
Residual
-7.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.